CompletedNCT04227457LATINO LungUpdated Feb 20, 2024

Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America

An observational study in Lung Cancer, sponsored by Latin American Cooperative Oncology Group. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Latin American Cooperative Oncology Group · Observational

Study type: Observational
Model: Case-only
Time perspective: Prospective
Enrollment: 700
Ages: 18 Years and older
Sex: All

Study summary

To describe the overall survival of advanced NSCLC in Latin America.

Read the detailed description

To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
To describe treatment responses, progression and survival times.
To describe reasons for treatment discontinuation
To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.

Conditions studied

Lung Cancer

Browse trials for

Lung Neoplasms 7,243

Keywords

Lung Cancer

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 700 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Latin American Cooperative Oncology Group is the lead sponsor of 46 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

The LATINO Lung study will prospectively recruit a minimum of 700 and up to 800 patients with advanced NSCLC, including locally advanced disease not amenable to curative treatment or metastatic disease from sites in Argentina, Brazil, Chile, Colombia, and Mexico. Other countries may be invited to participate.

Patients will be recruited during an initial study period of 3 months, or more to reach the study minimum sample size, and will be followed for 3 years.

Eligibility criteria

Inclusion Criteria:

Patients aged 18 years or older;
Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
Histologically or cytologically confirmed advanced NSCLC:
1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
2. Stage IV metastatic disease (de novo or distant relapse)
Any NSCLC histological subtype and molecular mutation;
Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
Access to patient medical chart for data collection;
Willing and able to provide written informed consent and privacy authorization for the release of personal health information.

Study design

Observational model: Case-only
Time perspective: Prospective
Enrollment: 700 participants (actual)
Target follow-up: 3 Years
Patient registry: Yes

What researchers measure

Primary outcomes

Overall survival of advanced NSCLC in Latin America
Time from randomization or initiation of treatment to patient death
Time frame: Annually, during 3 years

Secondary outcomes

Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
Description of the socioeconomical characteristics of the Latin America population with newly advanced NSCLC
Time frame: Annually, during 3 years
Description of pathological profile of advanced NSCLC
Analysis of histology and molecular markers of advanced NSCLC
Time frame: Annually, during 3 years
Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC
Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC
Time frame: Annually, during 3 years
Description of the treatment responses
Description of the treatment responses
Time frame: Annually, during 3 years
Description of Treatment discontinuation
Description of the reasons for treatment discontinuation
Time frame: Annually, during 3 years

Study locations

27 sites

Centro Oncologico Riojano
La Rioja, Rioja, Argentina
Instituto De Oncologia De Rosario
Santa Fe, Rosário, Argentina
Centro Medico San Roque
Córdoba, Tucumán, Argentina
CLION
Salvador, Bahia, Brazil
NOB
Salvador, Bahia, Brazil
CRIO
Fortaleza, Ceará, Brazil
Hospital Sírio- Libanês
Brasília, Distrito Federal, Brazil
ICTr
Curitiba, Paraná, Brazil
Hospital de Câncer de Londrina
Londrina, Paraná, Brazil
Hospital de Caridade de Carazinho
Carazinho, Rio Grande Do Sul, Brazil
CPO
Porto Alegre, Rio Grande Do Sul, Brazil
HCPA
Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Mãe de Deus
Porto Alegre, Rio Grande Do Sul, Brazil
Clínica Reichow
Blumenau, Santa Catarina, Brazil
CNT Itajaí
Itajaí, Santa Catarina, Brazil
Barretos
Barretos, São Paulo, Brazil
COI Américas
Rio De Janeiro, Brazil
INCA
Rio De Janeiro, Brazil
AC Camargo
São Paulo, Brazil
IBCC
São Paulo, Brazil
Fundación Arturo López Pérez
Providencia, Santiago, Chile
Clínica del Country
Chapinero, Bogotá, Colombia
Oncomedica
Montería, Córdoba, Colombia
Hospital Pablo Tobon Uribe
Robledo, Medellín, Colombia
Centro Médico Nacional Siglo XXI
Ciudad de mexico, Not Aplicable, Mexico
INCan
Ciudad de mexico, Not Aplicable, Mexico

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04227457
Lead sponsor: Latin American Cooperative Oncology Group
Collaborators: Bristol-Myers Squibb
Responsible party: Sponsor
First posted: Jan 13, 2020
Start date: Jul 25, 2018
Primary completion: Oct 4, 2021
Completion: Aug 4, 2023
Last update: Feb 20, 2024

Study contacts

Carlos Barrios

principal investigator · Latin American Cooperative Oncology Group

Gustavo Werutsky

principal investigator · Latin American Cooperative Oncology Group

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

Latin American Cooperative Oncology Group

Start the discussion